1 Planned or active medical trials for people with HER2-positive MBC

0 votes
6 views
asked Mar 23 in Android by bengal57bait (230 points)
one Prepared or active medical trials for sufferers with HER2-positive MBC with brain metastases Trial Trastuzumab Period I/II (NCT00397501) Section II (NCT01363986) Afatinib Phase II [100] (NCT01441596; LUX-breast   3) Lapatinib Phase I (NCT00614978; LAPTEM) Section I (NCT00470847) Neratinib Period II (NCT01494662) forty five HER2-positive MBC, C1 parenchymal mind lesion, and any range and sort of prior treatment (besides neratinib) allowed Neratinib (progressive mind metastases) or neratinib/ surgical resection (if qualified for craniotomy) Everolimus moreover trastuzumab and vinorelbine Intracranial RRb Recruiting eighteen HER2-positive MBC with recurrent or progressive mind metastases soon after surgery, WBRT, or SRS (or unsuitable for these common remedies) HER2-positive MBC, C1 parenchymal brain lesion, and CNS development Lapatinib in addition temozolomide MTD and DLT Ongoing, not recruiting Ongoing, not recruiting 120 HER2-positive MBC with CNS metastasis (C1 measurable mind lesion) Afatinib, afatinib/vinorelbine, or investigator's decision of remedy Benefit at twelve weeksa Recruiting seventy eight HER2-positive or HER2-negative MBC with CNS or mind metastases HER2-positive breast most cancers and C1 measurable brain metastasis Trastuzumab, methotrexate, and carboplatin with osmotic BBB disruption Trastuzumab furthermore WBRT OS Not but recruiting Recruiting Prepared accrual Populace Procedure Major endpoint(s) StatusBrain RRLapatinib as well as WBRTMTD and feasibilityEverolimus Phase II (NCT01305941) 35 HER2-positive breast most cancers with mind metastases (C1 measurable mind lesion), and any selection and kind of prior treatment (other than mTOR inhibitors or Navelbine) allowed RecruitingBBB blood rain barrier, CNS central nervous method, DLT dose-limiting toxicity, HER2 human epidermal progress variable receptor-2, MBC metastatic breast most cancers, MTD optimum tolerated dose, OS general survival, RR response level, SRS stereotactic radiosurgery, WBRT whole-brain radiotherapy Involves trials indexed on clinicaltrials.gov for which results are forthcoming, as of Octobera <a href="https://www.medchemexpress.com/Bitopertin.html">RG1678 Cancer</a> bBenefit <a href="https://www.medchemexpress.com/WAY-316606.html">WAY 316606 custom synthesis</a> described as absence of CNS or extra-CNS progression Modified RECIST criteriaradiation-induced <a href="https://www.medchemexpress.com/Bitopertin.html">Bitopertin Biological Activity</a> apoptosis of breast cancer cells in the HER2 level-dependent way in preclinical reports [56], but clinical studies are lacking. A section I/II demo of intrathecal trastuzumab in p.one Planned or energetic scientific trials for people with HER2-positive MBC with brain metastases Trial Trastuzumab Stage I/II (NCT00397501) Phase II (NCT01363986) Afatinib Period II [100] (NCT01441596; LUX-breast three) Lapatinib Section I (NCT00614978; LAPTEM) Stage I (NCT00470847) Neratinib Phase II (NCT01494662) 45 HER2-positive MBC, C1 parenchymal mind lesion, and any number and type of prior treatment (aside from neratinib) allowed Neratinib (progressive brain metastases) or neratinib/ surgical resection (if suitable for craniotomy) Everolimus moreover trastuzumab and vinorelbine Intracranial RRb Recruiting 18 HER2-positive MBC with recurrent or progressive mind metastases immediately after surgical procedure, WBRT, or SRS (or unsuitable for these typical remedies) HER2-positive MBC, C1 parenchymal mind lesion, and CNS progression Lapatinib in addition temozolomide MTD and DLT Ongoing, not recruiting Ongoing, not recruiting 120 HER2-positive MBC with CNS metastasis (C1 measurable brain lesion) Afatinib, afatinib/vinorelbine, or investigator's option of treatment Advantage at twelve weeksa Recruiting 78 HER2-positive or HER2-negative MBC with CNS or mind metastases HER2-positive breast most cancers and C1 measurable mind metastasis Trastuzumab, methotrexate, and carboplatin with osmotic BBB disruption Trastuzumab as well as WBRT OS Not yet recruiting Recruiting Planned accrual Populace Treatment method Key endpoint(s) StatusBrain RRLapatinib furthermore WBRTMTD and feasibilityEverolimus Phase II (NCT01305941) 35 HER2-positive breast most cancers with mind metastases (C1 measurable brain lesion), and any amount and kind of prior therapy (in addition to mTOR inhibitors or Navelbine) permitted RecruitingBBB blood rain barrier, CNS central nervous program, DLT dose-limiting toxicity, HER2 human epidermal development element receptor-2, MBC metastatic breast cancer, MTD optimum tolerated dose, OS all round survival, RR reaction price, SRS stereotactic radiosurgery, WBRT whole-brain radiotherapy Consists of trials indexed on clinicaltrials.gov for which ends are forthcoming, as of Octobera bBenefit described as absence of CNS or extra-CNS progression Modified RECIST criteriaradiation-induced apoptosis of breast cancer cells in a very HER2 level-dependent method in preclinical experiments [56], but scientific scientific studies are lacking. One particular tiny single-arm research of concurrent trastuzumab and WBRT shown basic safety and action using a radiographic response rate (RR) of seventy four   [57]. Randomized experiments of WBRT versus concurrent trastuzumab in addition WBRT have not been done. However, radiation could enhance the capacity of trastuzumab to cross the BBB. Within a research of six sufferers with HER2positive BM going through treatment method with trastuzumab and WBRT, the ratio of trastuzumab concentrations in serum and cerebral spinal fluid (CSF) was   420:one ahead of radiation and seventy six:1 right after radiation [55]. It really is probable which the efficacy of trastuzumab against intracerebral metastases may be elevated with enhanced delivery over the BBB. This is certainly supported by datademonstrating improved survival with trastuzumab intracerebral microinfusion (ICM) in HER2-positive breast cancer xenografts, without proof of medical or histological toxicity, when compared to intraperitoneal trastuzumab or ICM with saline [58]. Many scenario studies, mainly in HER2-positive leptomeningeal condition, have suggested intrathecal trastuzumab shown clinical reward and was normally very well tolerated [595]; even so, this remains experimental.

Please log in or register to answer this question.

...